NeoGenomics, Inc.

NeoGenomics, Inc.

15.25
USD
-0.16
(-1.04%)
-0.25EPS
2.37BMarket Cap
Feb 23Next Earn

Total Valuation

USD

As of September 30, 2026, NeoGenomics, Inc. carries a market capitalization of 2.37B, placing it among publicly traded companies globally. Its enterprise value stands at 2.68B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap2.37B
Enterprise Value2.68B

Important Dates

NeoGenomics, Inc.'s next confirmed earnings release is scheduled for February 23, 2027.

Earnings Date2/23/2027

Share Statistics

As of September 30, 2026, NeoGenomics, Inc. has 129.10M shares outstanding.

Shares Outstanding129.10M

Valuation Ratios

These figures are as of September 30, 2026. The price-to-sales ratio is 3.01, and the price-to-book ratio stands at 2.96.

PS Ratio3.01
PB Ratio2.96
P/TBV Ratio182.12
P/FCF Ratio-83.06
P/OCF Ratio553.40

Enterprise Valuation

As of September 30, 2026, NeoGenomics, Inc. trades at an EV/EBITDA multiple of 169.20 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 3.40 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 2.68B versus a market cap of 2.37B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales3.40
EV / EBITDA169.20

Financial Position

As of September 30, 2026, NeoGenomics, Inc. maintains a current ratio of 3.53, meaning it holds 3.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 56.10, indicating elevated leverage, while an interest coverage ratio of 4.88 demonstrates adequate ability to service its debt obligations.

Current Ratio3.53
Quick Ratio3.04
Debt / Equity56.10
Debt / EBITDA28.35
Interest Coverage4.88

Financial Efficiency

USD

Over the twelve months ended September 30, 2026, NeoGenomics, Inc. posted a negative return on equity (ROE) of -3.94, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -2.35, reflecting losses generated across the asset base. The company generates approximately 315,100.80 in revenue per employee across its workforce of 2,500.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 16.13 indicates how many times NeoGenomics, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)-3.94
Return on Assets (ROA)-2.35
Revenue Per Employee315,100.80
Employee Count2,500.00
Inventory Turnover16.13

Taxes

USD

Over the twelve months ended September 30, 2026, NeoGenomics, Inc. recorded an income tax benefit of -3.88M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -36.18M and -32.29M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

Income Tax-3.88M

Stock Price Statistics

USD

As of the close on November 17, 2026, NeoGenomics, Inc.'s stock has gained approximately 49.22% over the past 52 weeks. The 50-day moving average sits at 17.46, while the 200-day moving average is 13.02.

52-Week Price Change49.22%
50-Day Moving Average17.46
200-Day Moving Average13.02

Income Statement

USD

Over the twelve months ended September 30, 2026, NeoGenomics, Inc. generated 787.75M in revenue and converted that into -32.29M in net income, yielding earnings per share of -0.25. EBITDA reached 15.84M, while operating income came in at -48.74M.

Revenue787.75M
Gross Profit352.67M
Operating Income-48.74M
Pretax Income-36.18M
Net Income-32.29M
EBITDA15.84M
EBIT-49.37M
Earnings Per Share (EPS)-0.25

Balance Sheet

USD

As of September 30, 2026, NeoGenomics, Inc. holds 139.28M in cash and equivalents against 449.14M in total debt, resulting in a net debt position of 235.41M. Total book value stands at 800.64M, with working capital of 293.91M providing operational flexibility.

Cash & Cash Equivalents139.28M
Total Debt449.14M
Net Debt235.41M
Equity (Book Value)800.64M
Book Value Per Share6.20
Working Capital293.91M

Cash Flow

USD

NeoGenomics, Inc. produced 4.28M in operating cash flow over the twelve months ended September 30, 2026. After subtracting -32.86M in capital expenditures, free cash flow totaled -28.58M - equivalent to -0.22 per share.

Operating Cash Flow4.28M
Capital Expenditures-32.86M
Free Cash Flow-28.58M
FCF Per Share-0.22

Margins

Over the twelve months ended September 30, 2026, NeoGenomics, Inc. posted a gross margin of 44.77, reflecting its pricing power and cost economics. The operating margin of -6.19 and net profit margin of -4.10 provide insight into operational efficiency.

Gross Margin44.77
Operating Margin-6.19
Pretax Margin-4.59
Profit Margin-4.10
EBITDA Margin2.01

Dividends & Yields

These figures cover the twelve months ended September 30, 2026. Free cash flow yield is negative at -1.20: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -0.10, meaning NeoGenomics, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Shareholder Yield-0.10
FCF Yield-1.20

Stock Splits

NeoGenomics, Inc.'s most recent stock split took place on April 16, 2003 with a 100:1 split ratio.

Last Split Date4/16/2003
Split Ratio100:1

Scores

As of September 30, 2026, NeoGenomics, Inc. has an Altman Z-Score of 3.05, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score3.05